Biotech Values

[DewDiligence]

I hope so.

It’s much more than a hope, IMO, because it doesn’t make sense for MNTA to decline the opt-in on FoB’s where MNTA itself did the reverse engineering to make the programs viable.

The only way I could see MNTA declining the opt-in on compounds #3-#6 is if MNTA’s cash balance were expected to be drastically reduced as a result of losing the patent case against Amphastar.